< Back to situations

[ORGANIZATION]

U.S. Food and Drug Administration

Featured in 3 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [BUSINESS] [CRIME] [US] [BR] [GB]

GLP‑1 market, safety, usage & consumer trends

174 clusters · 621 sources · last updated

Latest: GLP‑1 weight‑loss drugs face scrutiny over microdosing and side‑effect risks

GLP‑1 receptor agonists have become a mainstream weight‑loss option, with usage spreading across primary‑care, tele‑health and Medicare‑CMS subsidies. Market value is projected near $105 billion by 2030. Safety signals c

[ACTIVE] [HEALTH] [US]

Merck Lipfendra oral PCSK9 approval

4 clusters · 51 sources · last updated

Latest: FDA approves Merck's oral PCSK9 inhibitor Lipfendra to lower LDL cholesterol

The U.S. Food and Drug Administration has confirmed approval of Merck’s Lipfendra (enlicitil‑de), the first once‑daily oral tablet that inhibits the PCSK9 protein. Clinical trials in more than 3,200 adults with primary h

Also covered in